Androgen receptor polymorphism and platelet reactivity in healthy men

Thrombosis Research

Volumn 126, Issue 1, 2010, Pages

  Kuliczkowski, W ^a   Filus, A ^a   Kuliczkowska Plaksej, J ^a   Trzmiel Bira, A ^a   Laczmanski, L ^a   Karolko, B ^a   Jedrzejuk, D ^a   Medras, M ^a   Milewicz, A ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHOLESTEROL; ESTRADIOL; GENOMIC DNA; GLUCOSE; PRASTERONE SULFATE; SEX HORMONE; TESTOSTERONE; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; AR PROTEIN, HUMAN;

ADULT; AGING; ANAMNESIS; BLOOD EXAMINATION; CAG REPEAT; CENTRIFUGATION; CONTROLLED STUDY; DNA ISOLATION; GENETIC POLYMORPHISM; HORMONE BLOOD LEVEL; HUMAN; LETTER; MALE; MORPHOLOGY; NORMAL HUMAN; PHYSICAL EXAMINATION; PLATELET REACTIVITY; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; GENETICS; MIDDLE AGED;

ADULT; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN;

EID: 77953121796     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.08.021     Document Type: Letter

References (20)

1. Ni H., Coady S., Rosamond W., Folsom A.R., Chambless L., Russell S.D., et al. Trends from 1987 to 2004 in sudden death due to coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 157 (2009) 46-52
2. Wu F.C., and von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 24 (2003) 183-217
3. Li S., Li X., Li J., Deng X., and Li Y. Inhibition of oxidative-stress-induced platelet aggregation by androgen at physiological levels via its receptor is associated with the reduction of thromboxane A2 release from platelets. Steroids 72 (2007) 875-880
4. Li S., Li X., Li J., Deng X., Li Y., and Cong Y. Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res 121 (2007) 127-134
5. Li S., Li X., and Li Y. Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction. Vascul Pharmacol 49 (2008) 14-18
6. Kintzel P.E., Chase S.L., Schultz L.M., and O'Rourke T.J. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 28 (2008) 1511-1522
7. Ajayi A.A., Mathur R., and Halushka P.V. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 91 (1995) 2742-2747
8. Ajayi A.A., and Halushka P.V. Castration reduces platelet thromboxane A2 receptor density and aggregability. QJM 98 (2005) 349-356
9. Cabeza M., Flores M., Bratoeff E., de la P.A., Mendez E., and Ceballos G. Intracellular Ca2+ stimulates the binding to androgen receptors in platelets. Steroids 69 (2004) 767-772
10. Khetawat G., Faraday N., Nealen M.L., Vijayan K.V., Bolton E., Noga S.J., et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 95 (2000) 2289-2296
11. Buchanan G., Yang M., Cheong A., Harris J.M., Irvine R.A., Lambert P.F., et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13 (2004) 1677-1692
12. Westberg L., Baghaei F., Rosmond R., Hellstrand M., Landen M., Jansson M., et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 86 (2001) 2562-2568
13. Zitzmann M., Brune M., Kornmann B., Gromoll J., von Eckardstein S., von Eckardstein A., et al. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 86 (2001) 4867-4873
14. Alevizaki M., Cimponeriu A.T., Garofallaki M., Sarika H.L., Alevizaki C.C., Papamichael C., et al. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin Endocrinol (Oxf) 59 (2003) 749-755
15. Hersberger M., Muntwyler J., Funke H., Marti-Jaun J., Schulte H., Assmann G., et al. The CAG repeat polymorphism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction. Clin Chem 51 (2005) 1110-1115
16. Freedman M.L., Pearce C.L., Penney K.L., Hirschhorn J.N., Kolonel L.N., Henderson B.E., et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 76 (2005) 82-90
17. Gilligan T., Manola J., Sartor O., Weinrich S.P., Moul J.W., and Kantoff P.W. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer 3 (2004) 98-103
18. Panz V.R., Joffe B.I., Spitz I., Lindenberg T., Farkas A., and Haffejee M. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine 15 (2001) 213-216
19. Krithivas K., Yurgalevitch S.M., Mohr B.A., Wilcox C.J., Batter S.J., Brown M., et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol 162 (1999) 137-142
20. Suzuki H., Akakura K., Komiya A., Ueda T., Imamoto T., Furuya Y., et al. CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 51 (2002) 219-224